WallStreetZenWallStreetZen

NASDAQ: CTMX
Cytomx Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CTMX

Based on 1 analyst offering 12 month price targets for Cytomx Therapeutics Inc.
Min Forecast
$3.00+100%
Avg Forecast
$3.00+100%
Max Forecast
$3.00+100%

Should I buy or sell CTMX stock?

Based on 1 analyst offering ratings for Cytomx Therapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTMX stock forecasts and price targets.

CTMX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-09

1 of 1

Forecast return on equity

Is CTMX forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is CTMX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CTMX revenue forecast

What is CTMX's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$87.0M+15.17%
Avg 2 year Forecast
$73.5M-2.75%
Avg 3 year Forecast
$69.6M-7.88%
CTMX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTMX revenue growth forecast

How is CTMX forecast to perform vs Biotechnology companies and vs the US market?
Company
-4.04%
Industry
52.23%
Market
10%
CTMX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTMX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTMX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CTMX$1.50$3.00+100.00%Hold
IOBT$1.51$9.00+496.03%Strong Buy
RVPH$4.37$16.00+266.13%Strong Buy
ANVS$9.94$33.67+238.70%Strong Buy
SEER$1.54N/AN/A

Cytomx Therapeutics Stock Forecast FAQ

Is Cytomx Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CTMX) stock is to Hold CTMX stock.

Out of 1 analyst, 0 (0%) are recommending CTMX as a Strong Buy, 0 (0%) are recommending CTMX as a Buy, 1 (100%) are recommending CTMX as a Hold, 0 (0%) are recommending CTMX as a Sell, and 0 (0%) are recommending CTMX as a Strong Sell.

If you're new to stock investing, here's how to buy Cytomx Therapeutics stock.

What is CTMX's revenue growth forecast for 2024-2026?

(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -4.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 52.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.

Cytomx Therapeutics's revenue in 2024 is $75,553,000.On average, 5 Wall Street analysts forecast CTMX's revenue for 2024 to be $5,828,838,515, with the lowest CTMX revenue forecast at $3,349,445,200, and the highest CTMX revenue forecast at $8,129,773,389. On average, 4 Wall Street analysts forecast CTMX's revenue for 2025 to be $4,922,009,721, with the lowest CTMX revenue forecast at $3,349,445,200, and the highest CTMX revenue forecast at $5,975,410,237.

In 2026, CTMX is forecast to generate $4,662,427,718 in revenue, with the lowest revenue forecast at $3,349,445,200 and the highest revenue forecast at $5,975,410,237.

What is CTMX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CTMX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CTMX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CTMX price target, the average CTMX price target is $3.00, with the highest CTMX stock price forecast at $3.00 and the lowest CTMX stock price forecast at $3.00.

The Wall Street analyst predicted that Cytomx Therapeutics's share price could reach $3.00 by Nov 9, 2024. The average Cytomx Therapeutics stock price prediction forecasts a potential upside of 100% from the current CTMX share price of $1.50.

What is CTMX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CTMX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.